RxDoctor Payments Data

Afshin Aminian

Orange, CANPI 1609805910

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $173,892 of the $257,246 with a category attached, or 67.6%. Medtronic accounts for 63.4% of it on its own, with 20 other manufacturers making up the rest.

$257,246in general payments, 2019–2025

Across 238 payments — averaging $1080.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$163K
  • Medicrea USA, Corp.$89K
  • Smaio SA$2K
  • Stryker$2K
  • Orthopediatrics Corp.$552
  • Spineart USA Inc$231
  • plus $1K from 15 others
$39,433in research payments, 2019–2025

Across 2 payments — averaging $19,717 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$39K

What the payments were for

  • Royalty or licence$173,89268%
  • Consulting fees$24,0259%
  • Speaking & faculty fees$47,70819%
  • Travel & lodging$3,6011%
  • Food & beverage$8,0203%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →